Table 3.
AEs by treatment group
| AEs | Aliskiren/HCTZ (n = 193) | Ramipril (n = 193) |
|---|---|---|
| Any AE, n (%) | 69 (35.8) | 72 (37.3) |
| Discontinuation due to AE, n (%) | 6 (3.1) | 3 (1.6) |
| Serious AE, n (%) | 4 (2.1) | 2 (1.0) |
| Suspected treatment-related AE, n (%) | 19 (9.8) | 20 (10.4) |
| Deaths, n (%) | 0 | 0 |
| AEs in ≥2% of patients in any treatment group, n (%) | ||
| Headache | 14 (7.3) | 17 (8.8) |
| Nasopharyngitis | 7 (3.6) | 5 (2.6) |
| Dizziness | 4 (2.1) | 7 (3.6) |
| Fatigue | 4 (2.1) | 4 (2.1) |
| Sinusitis | 4 (2.1) | 3 (1.6) |
| Frequent urination | 4 (2.1) | 0 |
| Upper respiratory tract infection | 2 (1.0) | 4 (2.1) |
| Back pain | 2 (1.0) | 4 (2.1) |
If a patient experienced more than one episode of a particular AE, the patient was counted only once for the event.